Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Company Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis was approved by the U.S. Food and Drug Administration in 2021 and subsequently authorized in Canada. Aurinia markets the therapy primarily in North America and supports patients through commercial, medical, and patient-assistance programs. The company has also conducted research into additional autoimmune and kidney-related applications for its technology.

Headquartered in Edmonton, Alberta, Aurinia was formerly known as Isotechnika Pharma before adopting its current name in 2013. The company has operated as a publicly traded biotechnology business focused on advancing treatments for patients with significant unmet medical needs.

Key Stats

• Today's Range: $15.74 to $16.06
• 50-Day Range: $14.57 to $17.27
• 52-Week Range: $10.90 to $19.25
• Volume: 813,423 shs
• Average Volume: 783,421 shs
• Market Capitalization: $2.11 billion
• P/E Ratio: 6.91
• Dividend Yield: N/A
• Price Target: $17.67
• Consensus Rating: Moderate Buy

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

Aurinia Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 210th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 2 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Aurinia Pharmaceuticals has a consensus price target of $17.67, representing about 11.6% upside from its current price of $15.83.

Amount of Analyst Coverage

Aurinia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 20.00%

Earnings Growth

Earnings for Aurinia Pharmaceuticals are expected to grow by 20.00% in the coming year, from $0.90 to $1.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurinia Pharmaceuticals is 6.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurinia Pharmaceuticals is 6.91, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.77.

Price to Book Value per Share Ratio

Aurinia Pharmaceuticals has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.19% of the float of Aurinia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 11.08, which indicates bearish sentiment.

Change versus previous month

Short interest in Aurinia Pharmaceuticals has recently decreased by 4.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurinia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Aurinia Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.69

News Sentiment

Aurinia Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

7 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AUPH
• CIK: 1600620
• Web: www.auriniapharma.com
• Phone: 250-708-4272
• Fax: 250-744-2498
• Employees: 128
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Aurinia Pharmaceuticals: $17.67
• High Price Target: $21.00
• Low Price Target: $16.00
• Potential Upside/Downside: +11.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.29
• Trailing P/E Ratio: 6.91
• Forward P/E Ratio: 17.59
• P/E Growth: N/A
• Net Income: $287.20 million
• Net Margins: 100.84%
• Pretax Margin: 51.48%
• Return on Equity: 26.11%
• Return on Assets: 19.89%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 5.42
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: $283.05 million
• Price / Sales: 7.44
• Cash Flow: $1.01 per share
• Price / Cash Flow: 15.74
• Book Value: $4.41 per share
• Price / Book: 3.59

Miscellaneous

• Outstanding Shares: 133,050,000
• Free Float: 119,214,000
• Market Cap: $2.11 billion
• Optionable: Optionable
• Beta: 1.60